Consensus of Chinese Experts on Neoadjuvant and Conversion Therapies for Hepatocellular Carcinoma: 2023 Update
Hepatocellular carcinoma (HCC) is a common malignancy in China, with high recurrence rate and low resection rate among patients first diagnosed. Preoperative treatments including neoadjuvant and conversion therapy have the potential to overcome these challenges. In December 2021, <i>Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma</i> was published. With the emersion of new evidence regarding the neoadjuvant and conversion therapies for HCC, the cooperative group brought together multidisciplinary researchers and scholars with experience in related fields to update the new edition (2023 Edition) for reference in China, including principle of the treatment strategies, the potential populations selection, treatment methods, multidisciplinary team, and future research for preoperative treatments. The new consensus aims to provide guidance for clinical application. Through the use of neoadjuvant therapy and conversion therapy, we can enhance the resection rate and reduce the recurrence of intermediate-to-advanced HCC patients, thereby improving survival outcomes.
Authors
- Shuqun Cheng (ORCID: https://orcid.org/0000-0001-6760-7470)
- Yongkun Sun (ORCID: https://orcid.org/0000-0003-3302-6023)
- Yefan Zhang
- Zhengqiang Yang (ORCID: https://orcid.org/0000-0001-9103-3534)
- Zhen Huang (ORCID: https://orcid.org/0000-0002-6320-548X)
- Haitao Zhao (ORCID: https://orcid.org/0000-0002-8765-3690)
- Zhenyu Zhu
- Xiaodong Wang (ORCID: https://orcid.org/0009-0006-9976-2866)
- Wen Zhang (ORCID: https://orcid.org/0000-0003-3150-2751)
- Xu Che (ORCID: https://orcid.org/0009-0000-8244-9212)
- Hong Zhao (ORCID: https://orcid.org/0000-0002-5253-6638)
- Guangming Li (ORCID: https://orcid.org/0000-0003-2286-7679)
- Jianguo Zhou
- Minshan Chen (ORCID: https://orcid.org/0000-0002-6116-5015)
- Xinyu Bi
- Jianqiang Cai
- Han Yue
- Liming Jiang (ORCID: https://orcid.org/0000-0002-2792-4321)
- Qing Chen (ORCID: https://orcid.org/0009-0005-3886-0350)
Institutions
- Sun Yat-sen University (CN)
- Second Military Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking University (CN)
- Peking Union Medical College Hospital (CN)
- Chinese PLA General Hospital (CN)
- Peking University Cancer Hospital (CN)
- Eastern Hepatobiliary Surgery Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- Beijing YouAn Hospital (CN)
Publication Details
- Journal
- Liver Cancer
- Published
- 2024-09-03
- DOI
- https://doi.org/10.1159/000541249
- Citations
- 11
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 4.06
Funders
- Beijing Xisike Clinical Oncology Research Foundation
- Chinese Academy of Medical Sciences